Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Thoracic and Cardiovascular Surgery
Published in: Indian Journal of Thoracic and Cardiovascular Surgery 6/2020

01-11-2020 | Calcineurin Inhibitors | Mini Review Article

A potential drug in the armamentarium of post-cardiac transplantation immunosuppression: belatacept

Authors: Dhruva Sharma, Neha Sharma

Published in: Indian Journal of Thoracic and Cardiovascular Surgery | Issue 6/2020

Login to get access

Abstract

Undeterred by all the advancement in the field of cardiac transplantation, heart transplant rejection remained its mammoth quandary. Management of heart transplant recipients has drastically improved with current regimens of immunosuppressive drugs. The adverse effects of calcineurin inhibitors are lacking with the use of belatacept, which is a costimulation inhibitor that interferes with the interaction between CD28 on T cells and the B7 ligands on antigen-presenting cells. It was originally approved for use in renal transplant recipients but it has shown promising results in heart transplant recipients.
Literature
1.
2.
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003:349–931 40.
3.
Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J. Summary of the US FDA approval of belatacept. Am J Transplant. 2012;12:554–62.CrossRef
4.
Ensor CR, Goehring KC, Iasella CJ, et al. Belatacept for maintenance immunosuppression in cardiothoracic transplantation: the potential frontier. Clin Transpl. 2018;32:e13363.
5.
Nguyen C, Shapiro R. New immunosuppressive agents in pediatric transplantation. Clinics (Sao Paulo). 2014;69:8–16.CrossRef
6.
Arora S, Tangirala B, Osadchuk L, Sureshkumar KK. Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation. Expert Opin Biol Ther. 2012;12:965–79.CrossRef
7.
Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907–15.
8.
Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5:443–53.
9.
Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation. 2001;72:377–84.
10.
Singh D. Immunosuppression for postcardiac transplant patients. J Pract Cardiovasc Sci. 2018;4:159–63.CrossRef
11.
Patterson C, Patterson KB. The history of heart transplantation. Am J Med Sci. 1997;314:190–7.CrossRef
12.
McGregor CG, Oyer PE, Shumway NE. Heart and heart-lung transplantation. Prog Allergy. 1986;38:346–65.PubMed
13.
Iasella CJ, Winstead RJ, Moore CA, et al. Maintenance belatacept-based immunosuppression in lung transplantation recipients who failed calcineurin inhibitors. Transplantation. 2018;102:171–7.
14.
Timofte I, Terrin M, Barr E, et al. Belatacept for renal rescue in lung transplant patients. Transpl Int. 2016;29:453–63.
15.
Enderby CY, Habib P, Patel PC, Yip DS, Orum S, Hosenpud JD. Belatacept maintenance in a heart transplant recipient. Transplantation. 2014;98:e74–5.CrossRef
16.
Kumar D, Yakubu I, Cooke RH, Halloran PF, Gupta G. Belatacept rescue for delayed kidney allograft function in a patient with previous combined heart-liver transplant. Am J Transplant. 2018;18:2613–4.CrossRef
17.
Austin DS, Douglas JA, Robert TC, Idelberto RB, Christopher PL. De novo belatacept in a kidney-after-heart transplant recipient. Transplantation Direct. 2020;6:e515.CrossRef
18.
Hui C, Kern R, Wojciechowski D, et al. Belatacept for maintenance immunosuppression in lung transplantation. J Investig Med High Impact Case Rep. 2014;2:2324709614546866.PubMedPubMedCentral
19.
Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014;14:1817–27.
20.
Knechtle SJ, Adams AB. Belatacept: is there BENEFIT for liver transplantation too? Am J Transpl. 2014;14:1717–8.CrossRef
21.
LaMattina JC, Hanish SI, Ottmann SE, et al. Safety of belatacept bridging immunosuppression in hepatitis C-positive liver transplant recipients with renal dysfunction. Transplantation. 2014;97:133–7.CrossRef
22.
Posselt AM, Szot GL, Frassetto LA, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010;90:1595–601.
23.
Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535–46.CrossRef
24.
Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10:547–57.
25.
Durrbach A, Pestana JM, Florman S, et al. Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant. 2016;16:3192–201.
Metadata
Title
A potential drug in the armamentarium of post-cardiac transplantation immunosuppression: belatacept
Authors
Dhruva Sharma
Neha Sharma
Publication date
01-11-2020
Publisher
Springer Singapore
Published in
Indian Journal of Thoracic and Cardiovascular Surgery / Issue 6/2020
Print ISSN: 0970-9134
Electronic ISSN: 0973-7723
DOI
https://doi.org/10.1007/s12055-020-00991-4

Other articles of this Issue 6/2020

Indian Journal of Thoracic and Cardiovascular Surgery 6/2020 Go to the issue

Review Article

Chylothorax caused by blunt chest trauma: a review of literature

Case report

Hemoptysis as a rare presenting symptom of hypertrophic obstructive cardiomyopathy

Invited Editorial

Annuloplasty for mitral valve repair in degenerative disease: to be flexible or to be rigid? That’s still the question

Original Article

Surgical outcomes for pediatric congenital lung malformation: 13 years’ experience

CRITICAL APPRAISAL OF TRIALS

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial and the appropriateness of revascularization

CORRESPONDENCE

Prevention and management of suture piercel of intra-coronary shunt at off-pump coronary bypass surgery